---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-023629"
form_type: "8-K"
ticker: "ELTP"
cik: "0001053369"
company_name: "ELITE PHARMACEUTICALS INC /NV/"
filed_at: "2025-11-14T23:59:59+00:00"
generated_at: "2026-05-16T19:39:06.215900+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Elite Pharma Q2 FY2026 revenue $36.3M (+92% YoY); operating income $8.2M (+136% YoY)

## Summary
- Consolidated revenue $36.3M for quarter ended Sept 30, 2025, up $17.4M or 92% vs prior year.
- Income from operations $8.2M, up $4.7M or 136% YoY.
- Growth driven by lisdexamfetamine product launches and strong Elite label product lines.
- Conference call scheduled for Monday, Nov 17, 2025 at 11:30 AM EST.

## SEC filing metadata
- accession: 0001493152-25-023629
- form_type: 8-K
- ticker: ELTP
- cik: 0001053369
- company_name: ELITE PHARMACEUTICALS INC /NV/
- filed_at: 2025-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1053369/000149315225023629/0001493152-25-023629-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1053369/000149315225023629/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-023629
- JSON: https://secwatch.observer/filing/0001493152-25-023629.json
- Plain text: https://secwatch.observer/filing/0001493152-25-023629.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.